Merck & Co.
Search results
Pfizer Canada strives to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines. Our diverse portfolio offers a broad range of benefits and solutions to meet the needs of Canadians.
Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
175th Anniversary. For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases. Learn more about our history.
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. We strive to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines.
The Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is approved for people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months has not yet been established.
Health Canada has approved Pfizer's new bivalent COVID-19 vaccine that contains mRNA from both the original SARS-CoV-2 virus and the Omicron BA.4 and BA.5 variants.
pfizer-biontech covid-19 vaccine (covid-19 mrna vaccine) On September 16, 2021, Health Canada granted full approval (Notice of Compliance or NOC) for COMIRNATY™. The vaccine was initially authorized for use in Canada under an Interim Order Authorization on December 9, 2020 under the name Pfizer-BioNTech COVID-19 Vaccine.
KIRKLAND, QC, April 23, 2021 — Pfizer Canada today announced it has reached an agreement with the Government of Canada to supply up to 125 million doses of the Pfizer-BioNTech COVID-19 vaccine in 2022 and 2023, with options to supply up to 60 million additional doses in 2024.
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose ...
Kirkland, QC, January 17, 2022 -- Pfizer Canada announced today that Health Canada has authorized the use of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults (18 years of age and older) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for ...
